[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612731":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":28,"locations":36,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Taipei Medical University Shuang Ho Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Opicapone group",null,"PD patients undergo dopaminergic medication adjustments",[13],"Other: No Intervention: Observational Cohort",{"label":15,"type":10,"description":16,"interventionNames":17},"Safinamide group","PD patients undergoing dopaminergic medication adjustments",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"No Intervention: Observational Cohort","No intervention.",[9,15],[24],{"name":25,"affiliation":26,"role":27},"Chen-Chih Chung, MD","Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan","PRINCIPAL_INVESTIGATOR",[29,33],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+886-2-22490088","10670@s.tmu.edu.tw",{"name":34,"role":30,"phone":10,"phoneExt":10,"email":35},"Chien Tai Hong, MD, PhD","15004@s.tmu.edu.tw",[37],{"facility":38,"status":10,"city":39,"state":10,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Shuang Ho Hospital, Taipei Medical University","New Taipei City","235","Taiwan","TW",{"type":44,"coordinates":45},"Point",[46,47],121.45703,25.06199,{"lat":47,"lon":46},[50],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612731","fall-risk-assessment-in-parkinsons-disease-using-kinetikos-health-100612731",false,"NCT07257393","Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health","Validation of a Mobile Health Application for Fall Risk Assessment in Parkinson's Disease: A Comparative Study Before and After Dopaminergic Medication Adjustment","PD_FALLRISK","Inclusion Criteria:\n\n1. Age ≥20;\n2. PD diagnosis (MDS criteria);\n3. On levodopa monotherapy with motor fluctuations;\n4. Planned to start opicapone or safinamide;\n5. Consent provided.\n\nExclusion Criteria:\n\n1. Atypical\u002Fsecondary parkinsonism;\n2. Moderate-severe dementia;\n3. DBS\u002FMRgFUS\u002Fneurosurgery within 6 months;\n4. Severe comorbidities limiting test","ALL","20 Years",{"count":64,"type":65},100,"ESTIMATED","OBSERVATIONAL","This is a single-center, prospective observational study aiming to validate the Kinetikos Health App for fall risk assessment in PD patients undergoing dopaminergic medication adjustments.",[69],"Idiopathic Parkinsonism",[71,72,73,74,75,76,77],"Parkinson's disease","Fall risk","Motor fluctuation","Dopaminergic medication","Mobile health","Sit-to-Stand","Kinetikos Health App","NOT_YET_RECRUITING","2025-12-03",{"date":81,"type":82},"2025-12-04","ACTUAL",{"date":84,"type":65},"2025-12-01",{"date":86,"type":65},"2026-06-30",{"name":5,"class":6},1]